CagriSema and retatrutide illustrate two approaches to investigating obesity treatment. CagriSema combines cagrilintide with semaglutide. Retatrutide is a single investigational molecule designed to act at GLP-1, GIP and glucagon receptors. The number of components or receptor targets does not determine which treatment has the better benefit-risk balance.

Read each trial on its own terms

The REDEFINE 1 randomized trial evaluated coadministered cagrilintide and semaglutide in adults with overweight or obesity. Retatrutide now also has published phase 3 evidence, including a September 2026 report. Describing retatrutide as having only phase 2 data would therefore be out of date. These studies provide human evidence, which should be distinguished from mechanism-based predictions. REDEFINE 1 randomized trial 2026 retatrutide phase 3 trial

A comparison between separate trials is not the same as a randomized head-to-head comparison. Eligibility criteria, diabetes status, follow-up duration, treatment discontinuation and handling of missing data can all affect reported weight changes. An analysis that assumes continued treatment may answer a different question from one that estimates outcomes regardless of discontinuation.

Approval is a separate question

FDA's current communication identifies retatrutide and cagrilintide as unapproved substances and states that they cannot be used in compounding under the applicable federal conditions described there. An approved semaglutide product does not confer approval on a new combination, an isolated retail ingredient or a seller's blend. FDA concerns with unapproved GLP-1 drugs

Clinical interpretation also requires adverse-event reporting, tolerability, durability and effects on health outcomes beyond a scale reading. A larger average weight change is not automatically the best result for every population.

AXON's useful comparison is an evidence map, not a winner's podium. The two programs test different pharmacologic strategies, and their published results need population-specific interpretation. This article does not establish interchangeability or support combining research products outside a regulated study. Approval and labeling should be checked again immediately before any public use of this draft.